





TSE code: 9913

NIPPO LTD.

(TSE Code: 9913)

March 2024 Period 1st Quarter Financial Results

~Supplementary materials~

August 3, 2023
President
Yasuchika Iwasa


Consolidated Financial Results (1)

March 2024 Period 1Q



(Unit: Millions of JPY)


	March 2023 Period 1Q	March 2024 Period 1Q	YoY	Change
Net Sales	9,162	10,148	111%	+986
Operating Profit	438	487	111%	+49
Ordinary Profit	316	528	167%	+212
Profit	136	335	246%	+199



Consolidated Financial Results (2)

March 2024 Period 1Q





Full-year Forecast

March 2024 Period



~Although sales are expected to decline in the 2Q because of the production adjustments by major ASEAN customers, the full-year earnings forecast remains unchanged due to recovery from the 3Q onwards.~

	<u> </u>	Terrarriged du	c to recove	Ty Holli the 5Q oliwards.				
	March 2024 period 1Q (results)	March 2024 period (forecast)	Progress	Remarks (Unit: Millions of JPY)				
Net sales	10 140	28 000	26.1%	Outlook for Consolidated Full-Year Results In the 1Q, the mobility and medical & precision device				
ivet sales	10,148	38,900	20.176	business performed well, but the full-year earnings forecast announced on May 12, 2023 remains unchanged because of the				
Operating	487	1 920	26 6%	following reasons; orders will decrease in the 2Q due to production adjustments by major ASEAN customers, while they are expected to be recovered from the 3Q onwards and				
profit	407	1,830	20.076	Semiconductor supply shortages remain unresolved in some industries and regions				
Ordinary	F20	1 910	29.2%	② Soaring resource prices (including power costs) are continuing				
profit	528	1,810	29.2 /0	③ Efforts on economic security etc. in each country are affecting the supply chain				
5 6	225	4 270	00.40/	2. Annual dividend				
Profit	335	1,270	26.4%	Since the full-year consolidated earnings forecast has remained unchanged, the annual dividend of ¥40 per share is also unchanged.				
A	(March 2023 period)	40JPY		**These consolidated forecasts are based on available data as of				
Annual dividend	33JPY Per share	Per share		the date of this press release and performance may differ materially from these forecasts owing to a variety of factors. In the event that it is deemed necessary to revise the outlook for full-				
		·		year earnings forecasts, we will make another announcement. 3				

Results by Segments_ Electronics



(Unit: Millions of 1PV)

Net sales ratio by segments


42.1% Revenue↑
Profit↓

			(Office Printin	0113 01 31 17
	Mar 2023 period 1Q	Mar 2024 period 1Q	YoY	Change
Net sales	4,139	4,309	104%	+170
Operating Profit	306	282	92%	△ 24

1Q Summary

- Orders for smartphone-related parts decreased due to the impact of customers' continued production adjustments.
- Sales increased due to strong orders for wiring board materials for communication base stations and servers, the dry film business at the Vietnam factory, and the carrier business for wafer polishing at the Okinawa factory.
- Income decreased due to upfront expenses recorded for the start-up of the dry film business at the Thailand (Korat) factory.

Quarterly Progress



	Mar 2023 period	Mar 2024 period YoY (Forecast)		Change
Net sales	16,854	16,900	100%	+46
Operating Profit	1,245	1,245	100%	± 0

Full-year Forecast

- Orders for wiring board materials, the dry film business at the Vietnam factory, and the carrier business for wafer polishing at the Okinawa factory are expected to remain strong.
- Although the recovery of orders for smartphone-related parts and the future of the semiconductor market are uncertain, the full year sales and operating income are expected to remain almost unchanged from the previous year.


Results by Segments_ Mobility



(Unit: Millions of 1PY)

Net sales ratio by segments

40.5%




			(01	,	
	Mar 2023 Mar period 1Q pe		YoY	Change	
Net sales	3,620	4,150	115%	+530	
Operating Profit	378	418	111%	+40	

1Q Summary

- Orders received for powertrain components at the Thailand (Bangkok) factory decreased due to sluggish sales of customers' products for China.
- Regardless of the negative factor above, sales and profits increased due to strong orders received from domestic customers as their production recovered, as well as steady orders received at Indonesia and Vietnam factory.

Quarterly Progress



	Mar 2023 period	Mar 2024 period (Forecast)	YoY	Change
Net sales	15,337	15,400	100%	+63
Operating Profit	1,535	1,470	96%	△ 65

Full-year Forecast

- In the 2Q, orders are expected to be decreased due to the impact of decreasing orders at the Thailand (Bangkok) factory and production adjustments by major ASEAN customers. Due to the recovering order from the 3Q onwards, however, full-year sales are expected to remain almost unchanged from the previous year.
- Operating profit is expected to decline due to increasing expenses for upfront investment (further horizontal deployment of automation, product development that applies winding technology, etc.) and soaring resource prices (including power costs), which were estimated in the Medium-term Management Plan 2025.

Results by Segment Medical & Precision Devices



(Unit: Millions of 1PY)

Net sal	les	ratio
by seg	gm	ents


Revenue↑
Profit ↑

			(011161 1 11111	01.0 0. 5. 1,	
	Mar 2023 period 1Q		YoY	Change	
Net sales	1,439	1,728	120%	+289	
Operating Profit	△14	36	_	+50	

1Q Summary

- Orders for medical equipment parts at the Thai (Korat) factory remained strong.
- Sales and profits of printer-related parts increased due to steady orders received at the Vietnam factory and the Philippines factory, even though orders received at the Thailand (Korat) factory decreased due to production cutbacks due to changes in customers' supply chains and supply shortages of semiconductors and electronic components.

Quarterly Progress



	Mar 2023 period	Mar 2024 period (Forecast)	YoY	Change	
Net sales	6,889	6,900	100%	+11	
Operating Profit	126	100	79%	△ 26	

Full-year Forecast

- Orders for medical equipment parts at the Thai (Korat) factory are expected to remain firm.
- The order outlook for printer-related parts is uncertain due to changes in customers' production sites and fluctuations in production volume.
- Full-year sales are expected to remain almost unchanged from the previous year because orders for medical equipment parts will cover the decrease in orders for printer-related parts. Profit, on the other hand, is expected to decrease due to the increased expenses for upfront investment (increase in domestic production capacity of medical equipment parts) set forth in the medium-term management plan.


Copyright

*The values are before consolidation adjustments between segments.


Medium-Term Management Plan 2025







■ ROE: showing shareholders' equity efficiency



Medium-Term Management Plan 2025 - Net Sales and Operating Profit by segment



(Unit: JPY billion)¥

(one: 31 1 billion) 1							
		FY2022		FY2023	FY2024	FY2025	
Flootropica	Net Sales	16.85		16.90	17.50	18.10	
Electronics	Operating Profit	1.24		1.24	1.26	1.30	
Mobility	Net Sales	15.33		15.40	15.90	16.50	
Mobility	Operating Profit	1.53	\rightarrow	1.47	1.50	1.54	
Medical and	Net Sales	6.88		6.90	7.20	7.50	
Precision Devices	Operating Profit	0.12		0.10	0.15	0.20	
Company-wide expenses (including development	Net Sales	△ 0.18		△ 0.30	△ 0.30	△ 0.30	
expenses) and adjustments	Operating Profit	△ 0.98		△ 0.98	△ 1.01	△ 1.04	
Consolidated	Net Sales	38.88		38.90	40.30	41.80	
Total	Operating Profit	1.91		1.83	1.90	2.00	
**The exchange rates used to set Management Plan 2025 are calcul		Three-year cumulative operating profit 5.73					

[Reference] Consolidated Balance Sheet



(Unit: Millions of JPY)

March 2024 Period 1Q

(Offic. Millions of							113 01 31 1/						
			March 2023 Period	March 2024 Period 1Q	Change					March 2023 Period	March 2024 Period 1Q	Change	
	Curi	rent assets	16,582	16,632	+50			Current liabilities		12,713	12,484	△229	
		Cash and deposits	4,910	5,161	+251		Liabilities			Notes and accounts payable-trade	7,725	7,746	+21
		Notes and accounts	7,340	7,524	+183	ַ ק			Short-term borrowing	2,481	2,357	△124	
		receivable-trade etc.	·	·					Other	2,506	2,380	△126	
Assets		Inventories	3,523	3,040	△483	g	S	Non-current liabilities		3,430	3,667	+236	
		Triveritories	3,323	3,040	△463				Long-term borrowing	920	859	△60	
		Other	er 807 906 +98			Other	2,510	2,807	+297				
U)	Non	-current assets	12,091	12,536	+444			Total		16,144	16,152	+7	
			12,031	12,550				Share capital		3,137	3,137	-	
		Property, plant and equipment	8,230	8,369	+139	ואכר	2	Capital surplus, Retained earnings, Treasury shares		7,465	7,512	+47	
		Intangible assets	380	393	+12	בר מסטכנס		Accumulated other comprehensive income		1,925	2,365	+440	
		Investments and other assets	3,480	3,773	+292			Non-controlling interests		1	1	△0	
		outer assets						Tota	I	12,530	13,017	+487	
		Total	28,674	29,169	+494	Т	ota	otal		28,674	29,169	+494	

Contacts



NIPPO LTD.

Corporate Planning Division Mizuguchi, Fujinami, Koshimizu

Telephone: +81-52-218-3161

HP: https://www.nip.co.jp/english/

Cautionary Statement with Respect to the Forward-Looking Statements

This document aims to provide information only to investors and not to solicit transactions. The forward-looking statements in this document reflect our plans and expectations and are not guarantees of future performance. Be aware that our future performance may differ from the current forecasts. In addition, descriptions of business performance, etc. here are based on reliable data, but we cannot guarantee the accuracy and safety of such data. Finally, this document is provided on the assumption that investors will use it at their own discretion and responsibility for any purpose whatsoever, and we will not be responsible for it in any event.

To note; the exchange rate used in this forecasts are 1USD = 133JPY 1TB = 3.8JPY

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.